The Digital Pill Grows Up: Remepy's Hire Signals a Paradigm Shift

NEW YORK, NY – September 16, 2026 — For the last half-decade, the digital health sector has been a graveyard of good intentions. We watched early pioneers of "digital therapeutics" attempt to sell standalone software as medicine, only to collide with a healthcare system that fundamentally refused to pay for apps the way it pays for pills. The market did not necessarily reject the underlying science; it rejected the commercial friction. Now, a clinical-stage biopharmaceutical startup named Remepy is betting the house on a radically different approach—and they just hired a traditional pharmaceutical heavyweight to prove it.

Today, the company announced the appointment of Dr. Eran Harary as Chief Medical Officer, effective October 1. Dr. Harary, formerly the Senior Vice President and Global Head of Early Clinical Development at Teva Pharmaceuticals, steps into the executive suite just as his new employer prepares to launch a global Phase III trial for its lead candidate, Hybridopa.

The transition of a traditional pharma executive into a tech-bio startup is not just a routine personnel update. It is a calculated signal to the market, the FDA, and the broader medical community that the era of treating software as a novelty is over. We are entering the age of the "Hybrid Drug."

The Regulatory Pivot: Surviving the Digital Health Graveyard

To understand the significance of this moment, one must look at the failures of Digital Therapeutics (DTx) 1.0. Companies like Pear Therapeutics—which filed for Chapter 11 bankruptcy in 2023—attempted to commercialize software applications as standalone prescription products. They suffered from a lack of dedicated reimbursement codes, resistance from prescribing physicians forced to manage non-integrated clinical workflows, and low patient adherence once the novelty of a medical app wore off.

The hybrid approach shifts the economic and clinical model entirely. Instead of prescribing an app instead of a drug, the therapy packages the software with the drug under a unified prescription.

This architecture is built on two layers. First, the pharmacological layer targets underlying biochemistries—such as receptor mechanics or neurotransmitter deficiencies. Second, the behavioral-digital layer delivers an adaptive, AI-driven daily regimen of motor-cognitive tasks and neuromodulatory exercises designed to activate neuroplasticity.

Crucially, this aligns perfectly with evolving U.S. FDA regulatory frameworks. Under the FDA’s Prescription Drug Use-Related Software (PDURS) guidance, if software disseminated by a drug sponsor produces clinical evidence showing added benefit over the drug alone, that benefit can be incorporated directly into the FDA-approved drug label. It is a brilliant bypass of the DTx 1.0 reimbursement trap. By riding the rails of existing pharmaceutical distribution channels, this new class of medicine avoids the payer friction that killed its predecessors.

A Heavyweight Steps into the Ring

The recruitment of Dr. Harary addresses a primary obstacle that earlier digital therapeutic companies failed to clear: traditional pharmaceutical credibility and regulatory trial execution.

Dr. Harary is not a Silicon Valley technologist; he is a board-certified psychiatrist with over two decades of drug development experience across the central nervous system, psychiatric, and rare neurological disorder spaces. During his tenure at Teva, Lundbeck, and Pfizer, he navigated FDA Advisory Committees, IND filings, Phase III pivotal designs, and NDA approvals. Notably, he led the clinical advancement of UZEDY, an extended-release subcutaneous injection approved for schizophrenia and bipolar I disorder, and contributed heavily to the development of AUSTEDO.

"We are creating a new category of drugs, and the regulatory environment is evolving to support it. Bringing Eran on board at this pivotal stage ensures we have the leadership in place to shape the future of Hybrid Drugs and bring this new class of medicine to patients through the standard prescription model," said Michal Tsur, PhD, and Or Shoval, Co-CEOs of Remepy, in a joint statement.

The sentiment was echoed by the new CMO himself, who noted the historical blind spot in modern drug development.

"For decades, we've invested billions in optimizing drugs while overlooking the enormous therapeutic value of non-pharmaceutical interventions that potentially add to the beneficial effect of the molecule alone," said Dr. Harary. "Today, advances in clinical development, digital technologies, AI, and an evolving regulatory landscape make it possible to unlock the value of combining drugs with digital therapeutic interventions. Remepy has built the first platform to do this with scientific rigor, and I believe Hybrid Drugs will become an important new category of medicine."

Biology Meets Code: Rewiring the Parkinson’s Brain

The immediate proving ground for this executive leadership will be the Hybridopa program, targeting Parkinson's disease.

For decades, the frontline treatment for Parkinson's has been levodopa, a drug that effectively replenishes dopaminergic tone but exhibits well-documented clinical degradation over time. Patients suffer from "off" episodes, motor fluctuations, and non-motor symptoms like depression and cognitive decline that pills alone cannot fix. Furthermore, levodopa does not slow the underlying neurodegeneration.

Hybridopa pairs immediate-release carbidopa/levodopa with an adaptive mobile software protocol engineered around four biological targets: brain plasticity, autonomic regulation, cognitive rebalancing, and reward tuning.

The clinical validation backing this up moves far beyond subjective patient surveys. In a Phase IIa double-blind trial published recently in Brain Communications, patients using the hybrid therapy achieved a staggering 9.7-point improvement on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), compared to just a 1.95-point improvement in the control group receiving levodopa and a sham application. Ninety percent of patients in the active cohort reached the threshold for clinically meaningful improvement.

Even more compelling is the neuroimaging data published in npj Parkinson's Disease. Using functional MRI and Diffusion Tensor Imaging, researchers demonstrated increased structural and functional connectivity in the thalamo-motor network corresponding to physical symptom reduction. The software wasn't just making patients feel better; it was actively rewiring the white-matter pathways in their brains.

The Pharma-Tech Playbook for 2026 and Beyond

From a commercial strategy perspective, the implications of this model are vast. The firm recently closed a $36 million Series A round, bringing its total equity capital to $62 million. But looking at the cap table reveals the true strategic play: the round was co-led by M Ventures, the strategic corporate venture arm of Merck KGaA.

This is not an isolated software developer trying to disrupt big pharma; it is a platform designed to partner with big pharma. By pairing a generic or patent-expiring small molecule with a proprietary, patent-protected digital protocol, pharmaceutical companies can generate a defensible new combination product entity. It is the ultimate lifecycle management tool, effectively resetting exclusivity cliffs while delivering genuinely superior patient outcomes.

The startup has already established an active collaboration with Merck KGaA to build hybrid combinations in oncology to attenuate treatment toxicity and modulate autonomic distress. Pipeline projects are also expanding into women's health, exploring the intersections of endocrine and behavioral health.

As we look toward the consumer and patient experience defining the latter half of this decade, the lines between pharmacology and behavioral technology are irrevocably blurring. The appointment of a veteran like Dr. Harary to shepherd a digital-molecular hybrid through Phase III trials is a watershed moment. It signals that the industry has finally figured out how to package, prescribe, and prove the efficacy of digital medicine. The digital pill has finally grown up, and the pharmaceutical landscape will never be the same.